Review
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 2902-2914
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.2902
Table 2 Safety and toxicity data regarding KRASG12C inhibitors in pancreatic ductal adenocarcinoma

Adagrasib (n = 21)[57]
Sotorasib (n = 38)[63]
Objective response rate (95%CI)33 (15-57)21 (10-37)
Disease control rate8184
Median duration of response (months)NA5.7 (1.6-non evaluable)
Progression-free survival (months) (95%CI)5.4 (3.9-8.2)4.0 (2.8-5.6)
Overall survival (months) (95%CI)8.0 (5.2-11.8)6.9 (5.0-9.1)
Grade 3-4 toxicities 2716
Dose reduction40 (solid tumours)13
Discontinuation for toxicity00